SCHEMBL6828933

SCHEMBL6828933

CN([C]=O)C1CCN(Cc2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.51
CHRM4 P08173 1/20 0.51
SIGMAR1 Q99720 5/20 0.50
DRD2 P14416 4/20 0.50
HTR2A P28223 4/20 0.50
HTR2C P28335 4/20 0.50
HTR2B P41595 4/20 0.50
OPRM1 P35372 3/20 0.50
CHRM2 P08172 4/20 0.48
CHRM3 P20309 4/20 0.48
BCHE P06276 1/20 0.48
BACE1 P56817 1/20 0.48
KCNH2 Q12809 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13024536 0.84 LTA4H (0.60) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL13634431 0.84 LTA4H (0.60) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL1911332 0.84 LTA4H (0.60) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL6828935 0.82 SIGMAR1 (0.53) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL3828313 0.82 ACHE (0.54) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL3817982 0.81 OPRM1 (0.59) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL1220330 0.81 OPRM1 (0.59) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL7498825 0.81 CHRM4 (0.55) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL7498815 0.81 CHRM4 (0.55) ACHECHRM4SIGMAR1DRD2HTR2A
SCHEMBL26618028 0.81 SIGMAR1 (0.57) ACHECHRM4SIGMAR1DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067999-A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands ASTRAZENECA AB (SE) 2004-04-08 US disclosed
EP-1358157-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS AstraZeneca AB (SE) 2003-11-05 EP disclosed
WO-2002051806-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067999-A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands NPY5R, NPY1R, NPY2R ACHE 1619/4885CHRM4 198/4885SIGMAR1 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.